首页 > 最新文献

The Journal of dermatology最新文献

英文 中文
The Predictive Value of Inflammatory Markers in the Severity and Mortality Risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 炎症标志物对Stevens-Johnson综合征/中毒性表皮坏死松解严重程度和死亡风险的预测价值
IF 2.7 Pub Date : 2025-12-19 DOI: 10.1111/1346-8138.70116
Xinjian Fan, Rui Liu, Xianwei Cao, Zhibin Zhang

Red blood cell distribution width-to-platelet ratio (RPR), red blood cell distribution width-to-hemoglobin ratio (RHR), red blood cell distribution width-to-albumin ratio (RAR), and prognostic nutritional index (PNI) have been implicated in disease severity and prognosis. However, their role in predicting severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) remains unclear. This study aimed to investigate the association between RPR, RHR, RAR, PNI and both disease severity and mortality in SJS/TEN patients. In this retrospective study, clinical data from 111 SJS/TEN patients were analyzed. RPR and other laboratory parameters were compared between survivors and non-survivors. The associations of RHR, PNI, RAR, and RPR with SJS/TEN severity were evaluated using Spearman or Pearson correlation analyses. Patients were categorized into survivor and non-survivor groups. Univariate and multivariate logistic regression analyses were employed to examine the correlations between these markers and mortality. The predictive performance of these indicators for SJS/TEN mortality was assessed using receiver operating characteristic (ROC) curve analysis. Correlation analysis revealed that RAR and RHR were positively correlated with SCORTEN, Re-SCORTRN, ABCD-10 and CRISTEN scores (p < 0.05), whereas PNI was negatively correlated (p < 0.05). Correlation analysis revealed that RPR was positively correlated with Re-SCORTRN, ABCD-10 and CRISTEN scores (p < 0.05). RAR, RPR, and RHR were identified as risk factors for mortality in SJS/TEN, while elevated PNI was a protective factor. The optimal cutoff values for RHR and RPR in predicting mortality were 0.13 (sensitivity 75%; specificity 73.6%) and 0.07 (sensitivity 90%; specificity 48.4%), respectively. These findings highlight the potential clinical utility of RHR (AUC = 0.841) and RAR (AUC = 0.729) as meaningful biomarkers for assessing SJS/TEN severity and associated mortality.

红细胞分布宽度与血小板比(RPR)、红细胞分布宽度与血红蛋白比(RHR)、红细胞分布宽度与白蛋白比(RAR)和预后营养指数(PNI)与疾病严重程度和预后有关。然而,它们在预测Stevens-Johnson综合征/中毒性表皮坏死松解症(SJS/TEN)的严重程度和死亡率中的作用尚不清楚。本研究旨在探讨SJS/TEN患者RPR、RHR、RAR、PNI与疾病严重程度和死亡率的关系。在这项回顾性研究中,分析了111例SJS/TEN患者的临床资料。比较幸存者和非幸存者的RPR和其他实验室参数。采用Spearman或Pearson相关分析评估RHR、PNI、RAR和RPR与SJS/TEN严重程度的相关性。患者被分为幸存者组和非幸存者组。采用单因素和多因素logistic回归分析来检验这些标志物与死亡率之间的相关性。采用受试者工作特征(ROC)曲线分析评估这些指标对SJS/TEN死亡率的预测性能。相关分析显示,RAR、RHR与SCORTEN、Re-SCORTRN、ABCD-10、CRISTEN评分呈正相关(p
{"title":"The Predictive Value of Inflammatory Markers in the Severity and Mortality Risk of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.","authors":"Xinjian Fan, Rui Liu, Xianwei Cao, Zhibin Zhang","doi":"10.1111/1346-8138.70116","DOIUrl":"https://doi.org/10.1111/1346-8138.70116","url":null,"abstract":"<p><p>Red blood cell distribution width-to-platelet ratio (RPR), red blood cell distribution width-to-hemoglobin ratio (RHR), red blood cell distribution width-to-albumin ratio (RAR), and prognostic nutritional index (PNI) have been implicated in disease severity and prognosis. However, their role in predicting severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) remains unclear. This study aimed to investigate the association between RPR, RHR, RAR, PNI and both disease severity and mortality in SJS/TEN patients. In this retrospective study, clinical data from 111 SJS/TEN patients were analyzed. RPR and other laboratory parameters were compared between survivors and non-survivors. The associations of RHR, PNI, RAR, and RPR with SJS/TEN severity were evaluated using Spearman or Pearson correlation analyses. Patients were categorized into survivor and non-survivor groups. Univariate and multivariate logistic regression analyses were employed to examine the correlations between these markers and mortality. The predictive performance of these indicators for SJS/TEN mortality was assessed using receiver operating characteristic (ROC) curve analysis. Correlation analysis revealed that RAR and RHR were positively correlated with SCORTEN, Re-SCORTRN, ABCD-10 and CRISTEN scores (p < 0.05), whereas PNI was negatively correlated (p < 0.05). Correlation analysis revealed that RPR was positively correlated with Re-SCORTRN, ABCD-10 and CRISTEN scores (p < 0.05). RAR, RPR, and RHR were identified as risk factors for mortality in SJS/TEN, while elevated PNI was a protective factor. The optimal cutoff values for RHR and RPR in predicting mortality were 0.13 (sensitivity 75%; specificity 73.6%) and 0.07 (sensitivity 90%; specificity 48.4%), respectively. These findings highlight the potential clinical utility of RHR (AUC = 0.841) and RAR (AUC = 0.729) as meaningful biomarkers for assessing SJS/TEN severity and associated mortality.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145795782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides. 免疫分析显示GATA3是转化性蕈样真菌病的预后标志物。
IF 2.7 Pub Date : 2025-12-18 DOI: 10.1111/1346-8138.70070
Bruno de Castro E Souza, Denis Miyashiro, Jade Cury-Martins, Neusa Yuriko Sakai Valente, Luiz Fernando Ferraz da Silva, José Antonio Sanches

Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T-cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue for GATA3 (n = 20), T-bet (n = 22), and STAT3 (n = 22). Expression was quantified by image analysis integrated optical density per total area (IOD/area), standardized by z-score and correlated with survival. Seventeen patients with complete data underwent unsupervised clustering (k-means) and principal component analysis (PCA) based on marker expression profiles. High GATA3 expression was strongly associated with worse prognosis (median OS: 8.6 months vs. 41.7 months, p = 0.00094). T-bet and STAT3 expressions showed no significant individual association with survival. Clustering analysis revealed three distinct immunoprofiles: (1) low expression of all markers (intermediate survival, 28.1 months), (2) high STAT3 and T-bet expressions with intermediate GATA3 expression (longest survival, 53.1 months), and (3) high GATA3 expression with low STAT3 and T-bet expressions (poorest survival, 9.5 months). GATA3 is a robust prognostic marker in TMF, identifying patients with particularly poor outcomes. Its elevated expression delineates a Th2-skewed, immunosuppressive phenotype that may inhibit Th1/Th17 pathways via transcriptional repression. Integrative profiling reveals immunobiological subgroups with divergent prognoses, supporting GATA3 as a potential tool for risk stratification and a candidate for targeted intervention in TMF.

转化蕈样真菌病(TMF)是一种罕见的侵袭性皮肤t细胞淋巴瘤,其特征是存在较大的肿瘤细胞和较差的临床结果。对22例TMF患者进行回顾性队列分析,采用福尔马林固定石蜡包埋(FFPE)组织免疫组化检测GATA3 (n = 20)、T-bet (n = 22)和STAT3 (n = 22)。通过图像分析积分光密度(IOD/area)量化表达,通过z-score标准化表达,并与生存相关。17例数据完整的患者进行了基于标记表达谱的无监督聚类(k-means)和主成分分析(PCA)。高表达GATA3与预后不良密切相关(中位OS: 8.6个月vs. 41.7个月,p = 0.00094)。T-bet和STAT3的表达与生存率没有显著的个体相关性。聚类分析显示三种不同的免疫特征:(1)所有标记物低表达(中等生存期,28.1个月);(2)STAT3和T-bet高表达,中等GATA3表达(最长生存期,53.1个月);(3)GATA3高表达,低表达STAT3和T-bet(最低生存期,9.5个月)。GATA3是TMF的一个可靠的预后指标,可识别预后特别差的患者。其升高的表达描述了一种th2偏斜的免疫抑制表型,可能通过转录抑制抑制Th1/Th17途径。综合分析揭示了预后不同的免疫生物学亚组,支持GATA3作为风险分层的潜在工具和靶向干预TMF的候选工具。
{"title":"Immunoprofiling Reveals GATA3 as a Prognostic Marker in Transformed Mycosis Fungoides.","authors":"Bruno de Castro E Souza, Denis Miyashiro, Jade Cury-Martins, Neusa Yuriko Sakai Valente, Luiz Fernando Ferraz da Silva, José Antonio Sanches","doi":"10.1111/1346-8138.70070","DOIUrl":"https://doi.org/10.1111/1346-8138.70070","url":null,"abstract":"<p><p>Transformed mycosis fungoides (TMF) is a rare, aggressive variant of cutaneous T-cell lymphoma characterized by the presence of large neoplastic cells and poor clinical outcomes. A retrospective cohort of 22 TMF patients was analyzed using immunohistochemistry on formalin-fixed, paraffin-embedded (FFPE) tissue for GATA3 (n = 20), T-bet (n = 22), and STAT3 (n = 22). Expression was quantified by image analysis integrated optical density per total area (IOD/area), standardized by z-score and correlated with survival. Seventeen patients with complete data underwent unsupervised clustering (k-means) and principal component analysis (PCA) based on marker expression profiles. High GATA3 expression was strongly associated with worse prognosis (median OS: 8.6 months vs. 41.7 months, p = 0.00094). T-bet and STAT3 expressions showed no significant individual association with survival. Clustering analysis revealed three distinct immunoprofiles: (1) low expression of all markers (intermediate survival, 28.1 months), (2) high STAT3 and T-bet expressions with intermediate GATA3 expression (longest survival, 53.1 months), and (3) high GATA3 expression with low STAT3 and T-bet expressions (poorest survival, 9.5 months). GATA3 is a robust prognostic marker in TMF, identifying patients with particularly poor outcomes. Its elevated expression delineates a Th2-skewed, immunosuppressive phenotype that may inhibit Th1/Th17 pathways via transcriptional repression. Integrative profiling reveals immunobiological subgroups with divergent prognoses, supporting GATA3 as a potential tool for risk stratification and a candidate for targeted intervention in TMF.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety Evaluation of Fine Bubble Shower Washing for Patients With Atopic Dermatitis: A Double-Blind, Randomized, Prospective Crossover Clinical Trial. 细泡淋浴洗对特应性皮炎患者的安全性评价:一项双盲、随机、前瞻性交叉临床试验。
IF 2.7 Pub Date : 2025-12-17 DOI: 10.1111/1346-8138.70117
Hiroshi Kato, Risa Tamagawa-Mineoka, Eiji Nakatani, Kenichi Yoshimura, Yukiko Yasui, Kasumi Kato, Motoki Nakamura, Ako Kurachi, Soshi Takeda, Akimichi Morita

Atopic dermatitis (AD) involves chronic eczema resulting from barrier dysfunction. Fine bubble (FB) technology generates microbubbles (< 100 μm) and ultrafine bubbles (< 1 μm) for surfactant-sparing cleansing. We assessed the short-term safety of an FB shower in AD. In this double-blind, randomized, crossover study, adults with mild AD completed two 2-week periods separated by a 2-week washout in sequence. Bathing instructions and petrolatum moisturizer use were standardized and enforced. The Eczema Area and Severity Index (EASI) was scored using whole-body photographs by a blinded team. Transepidermal water loss (TEWL) and stratum corneum hydration were measured on Days 0, 14, and 28. Because baselines were unavailable for the second 2-week period, the primary analysis compared Day 0-14 changes between groups using baseline-adjusted analysis of covariance; Day 0-28 changes were also explored. The primary outcomes were EASI changes; TEWL and hydration were the secondary outcomes. Groups used a conventional shower (control) first and then FB shower second or vice versa (once each). Twenty-three participants were analyzed (mean age 40.9 ± 8 years; 83% male). Day 0-14 EASI changes did not differ between FB and control (0.62 ± 2.21 vs. 0.05 ± 0.68; F = 0.93, p = 0.35). EASI changes to Day 28 were nonsignificant (0.02 ± 1.65 vs. -0.03 ± 1.02; p = 0.90). TEWL changes for Days 0-14 (0.31 ± 4.75 vs. 1.09 ± 6.21 g/m2/h) and to Day 28 (5.49 ± 14.43 vs. -0.27 ± 5.28 g/m2/h) showed no between-group differences. Hydration changes were similar for Days 0-14 (5.53 ± 13.23 vs. 6.14 ± 7.96 AU) and to Day 28 (18.41 ± 10.33 vs. 21.09 ± 11.07 AU). No serious adverse events or discontinuations for worsening symptoms occurred. Under standardized, low-irritant conditions, the FB shower was well-tolerated by adults with mild AD and did not worsen severity or barrier indices over 4 weeks. However, the superiority of FB to a conventional shower was not demonstrated.

特应性皮炎(AD)涉及由屏障功能障碍引起的慢性湿疹。细泡(FB)技术产生微泡(2个/h),至第28天(5.49±14.43 vs -0.27±5.28 g/m2/h)组间无差异。第0-14天(5.53±13.23 AU对6.14±7.96 AU)和第28天(18.41±10.33 AU对21.09±11.07 AU)的水合变化相似。未发生严重不良事件或因症状恶化而停药。在标准化、低刺激性条件下,轻度AD患者对FB淋浴具有良好的耐受性,并且在4周内没有恶化严重程度或屏障指数。然而,并没有证明FB相对于传统淋浴器的优越性。
{"title":"Safety Evaluation of Fine Bubble Shower Washing for Patients With Atopic Dermatitis: A Double-Blind, Randomized, Prospective Crossover Clinical Trial.","authors":"Hiroshi Kato, Risa Tamagawa-Mineoka, Eiji Nakatani, Kenichi Yoshimura, Yukiko Yasui, Kasumi Kato, Motoki Nakamura, Ako Kurachi, Soshi Takeda, Akimichi Morita","doi":"10.1111/1346-8138.70117","DOIUrl":"https://doi.org/10.1111/1346-8138.70117","url":null,"abstract":"<p><p>Atopic dermatitis (AD) involves chronic eczema resulting from barrier dysfunction. Fine bubble (FB) technology generates microbubbles (< 100 μm) and ultrafine bubbles (< 1 μm) for surfactant-sparing cleansing. We assessed the short-term safety of an FB shower in AD. In this double-blind, randomized, crossover study, adults with mild AD completed two 2-week periods separated by a 2-week washout in sequence. Bathing instructions and petrolatum moisturizer use were standardized and enforced. The Eczema Area and Severity Index (EASI) was scored using whole-body photographs by a blinded team. Transepidermal water loss (TEWL) and stratum corneum hydration were measured on Days 0, 14, and 28. Because baselines were unavailable for the second 2-week period, the primary analysis compared Day 0-14 changes between groups using baseline-adjusted analysis of covariance; Day 0-28 changes were also explored. The primary outcomes were EASI changes; TEWL and hydration were the secondary outcomes. Groups used a conventional shower (control) first and then FB shower second or vice versa (once each). Twenty-three participants were analyzed (mean age 40.9 ± 8 years; 83% male). Day 0-14 EASI changes did not differ between FB and control (0.62 ± 2.21 vs. 0.05 ± 0.68; F = 0.93, p = 0.35). EASI changes to Day 28 were nonsignificant (0.02 ± 1.65 vs. -0.03 ± 1.02; p = 0.90). TEWL changes for Days 0-14 (0.31 ± 4.75 vs. 1.09 ± 6.21 g/m<sup>2</sup>/h) and to Day 28 (5.49 ± 14.43 vs. -0.27 ± 5.28 g/m<sup>2</sup>/h) showed no between-group differences. Hydration changes were similar for Days 0-14 (5.53 ± 13.23 vs. 6.14 ± 7.96 AU) and to Day 28 (18.41 ± 10.33 vs. 21.09 ± 11.07 AU). No serious adverse events or discontinuations for worsening symptoms occurred. Under standardized, low-irritant conditions, the FB shower was well-tolerated by adults with mild AD and did not worsen severity or barrier indices over 4 weeks. However, the superiority of FB to a conventional shower was not demonstrated.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Pediatric Case of Wells Syndrome Presenting With Recurrent Annular Erythema and Fever Successfully Treated With Baricitinib. 以反复出现的环状红斑和发热为表现的威尔斯综合征患儿一例,Baricitinib成功治疗。
IF 2.7 Pub Date : 2025-12-17 DOI: 10.1111/1346-8138.70106
Risa Yamada, Hisamu Tanaka, Kentaro Yamamura, Tomoko Yoshida, Teruki Dainichi
{"title":"A Pediatric Case of Wells Syndrome Presenting With Recurrent Annular Erythema and Fever Successfully Treated With Baricitinib.","authors":"Risa Yamada, Hisamu Tanaka, Kentaro Yamamura, Tomoko Yoshida, Teruki Dainichi","doi":"10.1111/1346-8138.70106","DOIUrl":"https://doi.org/10.1111/1346-8138.70106","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Late-Recognized Nevus Comedonicus Without Blackish Plugs With Superimposed Acne Responsive to Adapalene. 对阿达帕林有反应的晚期无黑塞伴痤疮的粉刺痣。
IF 2.7 Pub Date : 2025-12-17 DOI: 10.1111/1346-8138.70115
Shoko Shiraki, Yuka Kato, Risa Nobuta, Toshifumi Nomura
{"title":"Late-Recognized Nevus Comedonicus Without Blackish Plugs With Superimposed Acne Responsive to Adapalene.","authors":"Shoko Shiraki, Yuka Kato, Risa Nobuta, Toshifumi Nomura","doi":"10.1111/1346-8138.70115","DOIUrl":"https://doi.org/10.1111/1346-8138.70115","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145769898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature. 阿普米司特成功治疗皱襞细菌性脓疱病2例报告并文献复习。
IF 2.7 Pub Date : 2025-12-15 DOI: 10.1111/1346-8138.70113
Luca Bettolini, Carlo Alberto Maronese, Stefano Bighetti, Giovanni Genovese, Luisa Sarno, Stefano Buffon, Francesca Laura Boggio, Federica Derlino, Angelo Valerio Marzano

Amicrobial pustulosis of the folds (APF) is a rare, chronic-relapsing neutrophilic dermatosis characterized by sterile pustules affecting major and minor skin folds. It predominantly affects women and is frequently associated with autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel disease, and autoimmune thyroiditis. Due to its rarity, standardized treatment guidelines are lacking, and management remains challenging. Systemic corticosteroids, dapsone, colchicine, methotrexate, and biologics have been employed with variable outcomes, but long-term control is often difficult to achieve. Apremilast, an oral phosphodiesterase-4 inhibitor with anti-inflammatory properties, has demonstrated efficacy in various neutrophilic dermatoses. We report two women with treatment-refractory APF who achieved clinical remission within 2 months of initiating apremilast, with sustained disease control at 6 months and successful corticosteroid tapering. A literature review of 78 APF cases confirmed a strong female predominance (93.6%) and frequent association with autoimmune conditions (91%). Systemic corticosteroids were the most frequently employed treatment but often failed to provide sustained disease control without the addition of other systemic agents. These cases represent the first reports of apremilast use in APF and suggest its potential as a safe and effective steroid-sparing option in patients with refractory disease. Further studies are needed to validate its role in this setting.

皱褶菌性脓疱病(APF)是一种罕见的慢性复发性中性粒细胞皮肤病,其特征是无菌脓疱影响皮肤的主要和次要皱褶。它主要影响女性,经常与自身免疫性疾病,如系统性红斑狼疮、炎症性肠病和自身免疫性甲状腺炎有关。由于其罕见,缺乏标准化的治疗指南,管理仍然具有挑战性。系统性皮质类固醇、氨苯砜、秋水仙碱、甲氨蝶呤和生物制剂的应用有不同的结果,但长期控制往往难以实现。阿普雷米司特是一种具有抗炎特性的口服磷酸二酯酶-4抑制剂,已被证明对多种中性粒细胞性皮肤病有效。我们报告了两名难治性APF妇女,她们在开始阿普米司特治疗后2个月内获得临床缓解,6个月时疾病持续控制,皮质类固醇逐渐减少。对78例APF病例的文献回顾证实,APF以女性为主(93.6%),且常与自身免疫性疾病相关(91%)。全身性皮质类固醇是最常用的治疗方法,但如果不添加其他全身性药物,通常无法提供持续的疾病控制。这些病例是APF中首次使用阿普米司特的报道,并表明它有可能成为难治性疾病患者安全有效的保留类固醇的选择。需要进一步的研究来证实它在这种情况下的作用。
{"title":"Amicrobial Pustulosis of the Folds Successfully Treated With Apremilast: Report of Two Cases and Review of the Literature.","authors":"Luca Bettolini, Carlo Alberto Maronese, Stefano Bighetti, Giovanni Genovese, Luisa Sarno, Stefano Buffon, Francesca Laura Boggio, Federica Derlino, Angelo Valerio Marzano","doi":"10.1111/1346-8138.70113","DOIUrl":"https://doi.org/10.1111/1346-8138.70113","url":null,"abstract":"<p><p>Amicrobial pustulosis of the folds (APF) is a rare, chronic-relapsing neutrophilic dermatosis characterized by sterile pustules affecting major and minor skin folds. It predominantly affects women and is frequently associated with autoimmune diseases such as systemic lupus erythematosus, inflammatory bowel disease, and autoimmune thyroiditis. Due to its rarity, standardized treatment guidelines are lacking, and management remains challenging. Systemic corticosteroids, dapsone, colchicine, methotrexate, and biologics have been employed with variable outcomes, but long-term control is often difficult to achieve. Apremilast, an oral phosphodiesterase-4 inhibitor with anti-inflammatory properties, has demonstrated efficacy in various neutrophilic dermatoses. We report two women with treatment-refractory APF who achieved clinical remission within 2 months of initiating apremilast, with sustained disease control at 6 months and successful corticosteroid tapering. A literature review of 78 APF cases confirmed a strong female predominance (93.6%) and frequent association with autoimmune conditions (91%). Systemic corticosteroids were the most frequently employed treatment but often failed to provide sustained disease control without the addition of other systemic agents. These cases represent the first reports of apremilast use in APF and suggest its potential as a safe and effective steroid-sparing option in patients with refractory disease. Further studies are needed to validate its role in this setting.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stratum Corneum Ceramide Abnormalities in Atopic Dermatitis: Pathophysiology and Implications for Disease Management. 特应性皮炎的角质层神经酰胺异常:病理生理学和疾病管理的意义。
IF 2.7 Pub Date : 2025-12-15 DOI: 10.1111/1346-8138.70098
Takashi Sakai

The stratum corneum, as the outermost layer of the skin, functions as a critical barrier that maintains cutaneous hydration and systemic homeostasis. Among its structural lipids, ceramides constitute the most abundant and diverse component. These molecules are essential for the formation of lamellar structures that secure barrier integrity. Increasing evidence has established that abnormalities in stratum corneum ceramides are not merely epiphenomena but fundamental contributors to the pathophysiology of atopic dermatitis (AD). In this review, we provide an overview of the structure, biosynthesis, and diversity of ceramides within the stratum corneum, followed by a discussion of their pivotal role in skin barrier function. We highlight recent insights into how ceramide abnormalities manifest in AD, including reduced total content, altered class distribution, and a shift toward shorter-chain fatty acids. Such alterations are associated with increased transepidermal water loss and impaired hydration. Mechanistic studies further reveal that type 2 cytokines, particularly IL-4 and IL-13, directly disrupt lipid metabolism by inhibiting enzymes, thereby establishing a vicious cycle of inflammation and barrier dysfunction. Beyond pathophysiology, advances in lipidomics and tape-stripping techniques now enable noninvasive assessment of stratum corneum ceramides. These analyses have revealed their utility as biomarkers of disease activity, therapeutic response, and relapse risk. Collectively, ceramides of the stratum corneum provide a unique window into the biology of AD. Their accessibility, mechanistic relevance, and prognostic potential underscore their importance not only for understanding disease pathogenesis but also for advancing personalized management and the concept of disease modification in AD.

角质层是皮肤的最外层,是维持皮肤水合作用和系统平衡的重要屏障。在其结构脂质中,神经酰胺是最丰富和最多样化的成分。这些分子对于确保屏障完整性的层状结构的形成至关重要。越来越多的证据表明,角质层神经酰胺的异常不仅仅是一种表观现象,而且是特应性皮炎(AD)病理生理的基本因素。本文综述了角质层神经酰胺的结构、生物合成和多样性,并讨论了它们在皮肤屏障功能中的关键作用。我们强调了最近关于神经酰胺异常如何在AD中表现的见解,包括总含量减少,类分布改变以及向短链脂肪酸的转变。这种改变与经皮失水增加和水合作用受损有关。机制研究进一步揭示,2型细胞因子,特别是IL-4和IL-13,通过抑制酶直接破坏脂质代谢,从而建立炎症和屏障功能障碍的恶性循环。除了病理生理学,脂质组学和胶带剥离技术的进步现在可以对角质层神经酰胺进行无创评估。这些分析揭示了它们作为疾病活动性、治疗反应和复发风险的生物标志物的效用。总的来说,角质层的神经酰胺为阿尔茨海默病的生物学提供了一个独特的窗口。它们的可及性、机制相关性和预后潜力强调了它们不仅对了解疾病发病机制,而且对推进AD的个性化管理和疾病改变概念的重要性。
{"title":"Stratum Corneum Ceramide Abnormalities in Atopic Dermatitis: Pathophysiology and Implications for Disease Management.","authors":"Takashi Sakai","doi":"10.1111/1346-8138.70098","DOIUrl":"https://doi.org/10.1111/1346-8138.70098","url":null,"abstract":"<p><p>The stratum corneum, as the outermost layer of the skin, functions as a critical barrier that maintains cutaneous hydration and systemic homeostasis. Among its structural lipids, ceramides constitute the most abundant and diverse component. These molecules are essential for the formation of lamellar structures that secure barrier integrity. Increasing evidence has established that abnormalities in stratum corneum ceramides are not merely epiphenomena but fundamental contributors to the pathophysiology of atopic dermatitis (AD). In this review, we provide an overview of the structure, biosynthesis, and diversity of ceramides within the stratum corneum, followed by a discussion of their pivotal role in skin barrier function. We highlight recent insights into how ceramide abnormalities manifest in AD, including reduced total content, altered class distribution, and a shift toward shorter-chain fatty acids. Such alterations are associated with increased transepidermal water loss and impaired hydration. Mechanistic studies further reveal that type 2 cytokines, particularly IL-4 and IL-13, directly disrupt lipid metabolism by inhibiting enzymes, thereby establishing a vicious cycle of inflammation and barrier dysfunction. Beyond pathophysiology, advances in lipidomics and tape-stripping techniques now enable noninvasive assessment of stratum corneum ceramides. These analyses have revealed their utility as biomarkers of disease activity, therapeutic response, and relapse risk. Collectively, ceramides of the stratum corneum provide a unique window into the biology of AD. Their accessibility, mechanistic relevance, and prognostic potential underscore their importance not only for understanding disease pathogenesis but also for advancing personalized management and the concept of disease modification in AD.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145764820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of Anti-SRP Antibody-Positive Necrotizing Myopathy That Initially Presented With Raynaud's Phenomenon and a Digital Ulcer. 抗srp抗体阳性坏死性肌病1例,最初表现为雷诺现象和数字溃疡。
IF 2.7 Pub Date : 2025-12-15 DOI: 10.1111/1346-8138.70114
Tomomichi Shimizu, Fumikazu Yamazaki, Akio Kondoh, Eimi Kato, Atsushi Mizuma, Eiichiro Nagata, Tomotaka Mabuchi
{"title":"A Case of Anti-SRP Antibody-Positive Necrotizing Myopathy That Initially Presented With Raynaud's Phenomenon and a Digital Ulcer.","authors":"Tomomichi Shimizu, Fumikazu Yamazaki, Akio Kondoh, Eimi Kato, Atsushi Mizuma, Eiichiro Nagata, Tomotaka Mabuchi","doi":"10.1111/1346-8138.70114","DOIUrl":"https://doi.org/10.1111/1346-8138.70114","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145759116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between Prurigo Nodularis and Malignancy: A Real-World Multicenter Retrospective Cohort Study. 结节性痒疹与恶性肿瘤的关系:一项真实世界多中心回顾性队列研究。
IF 2.7 Pub Date : 2025-12-12 DOI: 10.1111/1346-8138.70112
Yu-Hsiang Lin, Yu-Ching Wang, Tai-Li Chen, Ling-Chuan Jaun, Cheng-Jui Tsai, Chih-Chiang Chen, Cian-Hao Ye, Sheng-Hsiang Ma

Prurigo nodularis (PN) is a chronic inflammatory skin disorder associated with various systemic disorders. However, its potential link to increased malignancy risk remains unclear. We conducted a retrospective cohort study using the US Collaborative Network in the TriNetX database, encompassing data from January 1, 2016 to January 1, 2022. Adults diagnosed with PN (n = 10 941) were matched 1:1 with controls without PN (n = 10 941) based on demographics, comorbidities, and medication use. The primary outcome was the hazard ratio (HR) for malignancy occurring between 3 months and 5 years after the index date. The HRs and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Patients with PN exhibited a significantly increased risk of developing malignancies compared with the controls (HR 2.10; 95% CI 1.81-2.43). Notably, higher risks were observed for cutaneous squamous cell carcinoma (HR 4.24; 95% CI 2.69-6.69), basal cell carcinoma (HR 2.49; 95% CI 1.68-3.69), hematopoietic cancers (HR 1.97; 95% CI 1.26-3.06), gastrointestinal cancers (HR 1.87; 95% CI 1.24-2.81), respiratory system cancers (HR 1.86; 95% CI 1.23-2.82), and female genital cancers (HR 2.77; 95% CI 1.29-5.95). In conclusion, PN is associated with a significantly elevated risk of malignancy, particularly cutaneous cancers. These preliminary findings underscore the necessity for heightened clinical vigilance. Further prospective studies are needed to confirm this association, elucidate the underlying mechanisms, and evaluate the potential benefits of routine cancer screening in this high-risk population.

结节性痒疹(PN)是一种慢性炎症性皮肤病,与各种全身疾病相关。然而,其与恶性肿瘤风险增加的潜在联系尚不清楚。我们使用TriNetX数据库中的美国协作网络进行了一项回顾性队列研究,涵盖了2016年1月1日至2022年1月1日的数据。根据人口统计学、合并症和药物使用情况,诊断为PN的成年人(n = 10941)与无PN的对照组(n = 10941)进行1:1匹配。主要终点是指标日期后3个月至5年内发生恶性肿瘤的危险比(HR)。采用Cox比例风险模型计算hr和95%置信区间(ci)。与对照组相比,PN患者发生恶性肿瘤的风险显著增加(HR 2.10; 95% CI 1.81-2.43)。值得注意的是,皮肤鳞状细胞癌(风险比4.24,95% CI 2.69-6.69)、基底细胞癌(风险比2.49,95% CI 1.68-3.69)、造血癌(风险比1.97,95% CI 1.26-3.06)、胃肠道癌(风险比1.87,95% CI 1.24-2.81)、呼吸系统癌(风险比1.86,95% CI 1.23-2.82)和女性生殖器癌(风险比2.77,95% CI 1.29-5.95)的风险较高。总之,PN与恶性肿瘤,特别是皮肤癌的风险显著升高有关。这些初步发现强调了提高临床警惕性的必要性。需要进一步的前瞻性研究来证实这种关联,阐明潜在的机制,并评估在高危人群中进行常规癌症筛查的潜在益处。
{"title":"Association Between Prurigo Nodularis and Malignancy: A Real-World Multicenter Retrospective Cohort Study.","authors":"Yu-Hsiang Lin, Yu-Ching Wang, Tai-Li Chen, Ling-Chuan Jaun, Cheng-Jui Tsai, Chih-Chiang Chen, Cian-Hao Ye, Sheng-Hsiang Ma","doi":"10.1111/1346-8138.70112","DOIUrl":"https://doi.org/10.1111/1346-8138.70112","url":null,"abstract":"<p><p>Prurigo nodularis (PN) is a chronic inflammatory skin disorder associated with various systemic disorders. However, its potential link to increased malignancy risk remains unclear. We conducted a retrospective cohort study using the US Collaborative Network in the TriNetX database, encompassing data from January 1, 2016 to January 1, 2022. Adults diagnosed with PN (n = 10 941) were matched 1:1 with controls without PN (n = 10 941) based on demographics, comorbidities, and medication use. The primary outcome was the hazard ratio (HR) for malignancy occurring between 3 months and 5 years after the index date. The HRs and 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Patients with PN exhibited a significantly increased risk of developing malignancies compared with the controls (HR 2.10; 95% CI 1.81-2.43). Notably, higher risks were observed for cutaneous squamous cell carcinoma (HR 4.24; 95% CI 2.69-6.69), basal cell carcinoma (HR 2.49; 95% CI 1.68-3.69), hematopoietic cancers (HR 1.97; 95% CI 1.26-3.06), gastrointestinal cancers (HR 1.87; 95% CI 1.24-2.81), respiratory system cancers (HR 1.86; 95% CI 1.23-2.82), and female genital cancers (HR 2.77; 95% CI 1.29-5.95). In conclusion, PN is associated with a significantly elevated risk of malignancy, particularly cutaneous cancers. These preliminary findings underscore the necessity for heightened clinical vigilance. Further prospective studies are needed to confirm this association, elucidate the underlying mechanisms, and evaluate the potential benefits of routine cancer screening in this high-risk population.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epstein-Barr Virus (EBV) Reactivation-Associated Hemophagocytic Syndrome Following Drug-Induced Erythroderma With Mucosal Lesions. eb病毒(EBV)再激活与药物性红皮病伴粘膜病变后的噬血细胞综合征相关
IF 2.7 Pub Date : 2025-12-12 DOI: 10.1111/1346-8138.70092
Akiko Sekiguchi, Hitomi Fukumoto, Yasutaka Hirai, Rika Fukazu, Yu Sakamoto, Akihiko Uchiyama, Yukie Endo, Masahito Yasuda, Sei-Ichiro Motegi
{"title":"Epstein-Barr Virus (EBV) Reactivation-Associated Hemophagocytic Syndrome Following Drug-Induced Erythroderma With Mucosal Lesions.","authors":"Akiko Sekiguchi, Hitomi Fukumoto, Yasutaka Hirai, Rika Fukazu, Yu Sakamoto, Akihiko Uchiyama, Yukie Endo, Masahito Yasuda, Sei-Ichiro Motegi","doi":"10.1111/1346-8138.70092","DOIUrl":"https://doi.org/10.1111/1346-8138.70092","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145746513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
The Journal of dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1